Debt-free Balance SheetA zero-debt capital structure materially lowers refinancing and interest-rate risk and preserves financial optionality. Over a 2–6 month horizon this reduces the immediacy of solvency pressure, enabling management to prioritize scaling production or R&D without near-term debt servicing constraints.

Specialized Biopolymer CapabilitiesA focused technology stack—fermentation-based manufacturing and downstream processing for PHA and bacterial cellulose—constitutes a durable technical capability. This vertical specialization supports potential cost efficiencies and differentiation if the company scales, strengthening long-term commercial prospects versus generalist peers.

Lean Operating FootprintA small, focused team implies lower fixed personnel costs and operational agility. Over several months this lean structure can extend runway versus larger peers, allows targeted deployment of R&D spend, and reduces the incremental revenue required to move toward break-even if operating discipline continues.

Bears Say

Structurally Negative ProfitabilityRepeated negative gross profit and deep operating losses indicate the current cost base is materially misaligned with revenue scale. This structural unprofitability threatens long-term viability absent step-change improvements in margins or significant revenue scale, increasing reliance on external funding.

Consistent Cash BurnPersistent negative operating and free cash flows, with accelerating cash burn, create a durable financing need. Over a 2–6 month horizon this raises the probability of external capital raises, potential dilution, or constrained investment in commercialization, limiting sustainable growth execution.

Very Small, Declining RevenueVery small and recent declining revenues signal limited product-market traction and insufficient scale to absorb fixed costs. Without a credible path to sustained revenue growth, the company faces prolonged losses and weakened ability to leverage its technical capabilities into profitable commercial operations.

Bioextrax AB News

Is 85X0 a Buy, Before Earnings?

Bioextrax AB (85X0) is scheduled to report 4th quarter earnings on 02/19/2026. Regarding Q4 estimates, Wall Street analysts...

1M ago

BIOEX FAQ

What was Bioextrax AB’s price range in the past 12 months?

Bioextrax AB lowest stock price was kr1.60 and its highest was kr3.98 in the past 12 months.

What is Bioextrax AB’s market cap?

Bioextrax AB’s market cap is kr124.10M.

When is Bioextrax AB’s upcoming earnings report date?

Bioextrax AB’s upcoming earnings report date is May 14, 2026 which is in 55 days.

How were Bioextrax AB’s earnings last quarter?

Bioextrax AB released its earnings results on Feb 19, 2026. The company reported -kr0.11 earnings per share for the quarter, missing the consensus estimate of kr0 by -kr0.11.

Is Bioextrax AB overvalued?

According to Wall Street analysts Bioextrax AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioextrax AB pay dividends?

Bioextrax AB does not currently pay dividends.

What is Bioextrax AB’s EPS estimate?

Bioextrax AB’s EPS estimate is -0.1.

How many shares outstanding does Bioextrax AB have?

Bioextrax AB has 46,306,927 shares outstanding.

What happened to Bioextrax AB’s price movement after its last earnings report?

Bioextrax AB reported an EPS of -kr0.11 in its last earnings report, missing expectations of kr0. Following the earnings report the stock price went up 5.98%.

Which hedge fund is a major shareholder of Bioextrax AB?

Currently, no hedge funds are holding shares in SE:BIOEX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioextrax AB

Bioextrax AB (BIOEX) is a Swedish biotechnology company that focuses on developing and commercializing environmentally sustainable technologies for converting waste materials into valuable products. The company operates in the sectors of bio-based materials and waste management, offering innovative solutions for the production of bioplastics, animal feed, and other materials using its proprietary microbial processes.